Compare ARK Genomic Revolution ETF (ARKG) vs CDW Corp. (CDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs CDW Corp. — how do they compare? ARK Genomic Revolution ETF trades at $41.24, while CDW Corp. trades at $144.91 (market cap $18.45B). The key difference: CDW Corp. pays a 1.75% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, CDW Corp. nearer its low. Which is the better fit depends on your goals.
| ARKG | CDW | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $43.57 | $182.18 |
52-Week Low | $23.09 | $99.30 |
Market Cap | — | $18.45B |
Enterprise Value | — | $23.66B |
Dividend Yield | — | 1.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
CDW trades at $144.39, up 2.98% today, near its pivot point of $139 with resistance at $143. The stock shows strong profitability with a 44.16% ROE and consistent earnings beats in recent quarters. Recent news highlights AI infrastructure demand fueling growth, while the company increased its share repurchase program by $1 billion in May 2026. Technical indicators are bullish, with moving averages supporting upward momentum.
Outlook remains positive driven by AI demand and shareholder returns, but risks include margin pressure and high debt. Analysts are bullish with a $142.17 consensus target and 71% buy ratings. Investors should monitor Q2 2026 earnings against the $2.80 EPS estimate for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About CDW Corp.
CDW Corp is a value-added reseller operating in the U.S. (95% of sales) and Canada (5%). The company has more than 100,000 products on its line of cards that range from notebooks to data center software. Roughly half of CDW's revenue comes from midsize and large businesses, with the remaining from small businesses, government agencies, education institutions, and health-care organizations.
Read more on CDW →
